Dantrolene : From Malignant Hyperthermia to Alzheimer's Disease

Overview

Journal CNS Neurol Disord Drug Targets

Publisher Bentham Science Publishers

Specialties Neurology
Pharmacology

Date 2018 Jun 21

PMID 29921212

Citations 13

Authors

Yun Shi

Yong Wang

Huafeng Wei

Affiliations

Soon will be listed here.

Abstract

Dantrolene, a ryanodine receptor antagonist, is primarily known as the only clinically acceptable and effective treatment for Malignant Hyperthermia (MH). Inhibition of Ryanodine Receptor (RyR) by dantrolene decreases the abnormal calcium release from the Sarcoplasmic Reticulum (SR) or Endoplasmic Reticulum (ER), where RyR is located. Recently, emerging researches on dissociated cells, brains slices, live animal models and patients have demonstrated that altered RyR expression and function can also play a vital role in the pathogenesis of Alzheimer's Disease (AD). Therefore, dantrolene is now widely studied as a novel treatment for AD, targeting the blockade of RyR channels or another alternative pathway, such as the inhibitory effects of NMDA glutamate receptors and the effects of ER-mitochondria connection. However, the therapeutic effects are not consistent. In this review, we focus on the relationship between the altered RyR expression and function and the pathogenesis of AD, and the potential application of dantrolene as a novel treatment for the disease.

Citing Articles

Malignant hyperthermia during orthognathic surgery: a case report.

Li Y, Lin J, Luo W, Luo K, Luo L Hua Xi Kou Qiang Yi Xue Za Zhi. 2024; 42(6):828-831.

PMID: 39610082 PMC: 11669924. DOI: 10.7518/hxkq.2024.2024200.

Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation.

Zhang W, Zhao X, Bhuiyan P, Liu H, Wei H J Anesth Transl Med. 2024; 3(2):27-35.

PMID: 38826587 PMC: 11138240. DOI: 10.1016/j.jatmed.2024.04.002.

Effects of Intranasal Dantrolene Nanoparticles on Brain Concentration and Behavior in PS19 Tau Transgenic Mice.

Vera R, Hong N, Jiang B, Liang G, Eckenhoff M, Kincaid H J Alzheimers Dis. 2024; 98(2):549-562.

PMID: 38393915 PMC: 11178503. DOI: 10.3233/JAD-231337.

Amyotrophic Lateral Sclerosis Mechanism: Insights from the Models.

Chen L, Zhang S, Liu S, Gao S Cells. 2024; 13(1).

PMID: 38201303 PMC: 10778397. DOI: 10.3390/cells13010099.

Role of Calcium Modulation in the Pathophysiology and Treatment of Alzheimer's Disease.

Baracaldo-Santamaria D, Avendano-Lopez S, Ariza-Salamanca D, Rodriguez-Giraldo M, Calderon-Ospina C, Gonzalez-Reyes R Int J Mol Sci. 2023; 24(10).

PMID: 37240413 PMC: 10218981. DOI: 10.3390/ijms24109067.

References

Griffith C, Xie M, Qiu W, Sharp A, Ma C, Pan A . Aberrant expression of the pore-forming K channel subunit Kir6.2 in hippocampal reactive astrocytes in the 3xTg-AD mouse model and human Alzheimer's disease. Neuroscience. 2016; 336:81-101. DOI: 10.1016/j.neuroscience.2016.08.034. View

Oksanen M, Petersen A, Naumenko N, Puttonen K, Lehtonen S, Gubert Olive M . PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. Stem Cell Reports. 2017; 9(6):1885-1897. PMC: 5785689. DOI: 10.1016/j.stemcr.2017.10.016. View

Perkins G, Renken C, Martone M, Young S, Ellisman M, Frey T . Electron tomography of neuronal mitochondria: three-dimensional structure and organization of cristae and membrane contacts. J Struct Biol. 1997; 119(3):260-72. DOI: 10.1006/jsbi.1997.3885. View

Levy-Lahad E, Wasco W, Poorkaj P, Romano D, Oshima J, Pettingell W . Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269(5226):973-7. DOI: 10.1126/science.7638622. View

Stutzmann G . Calcium dysregulation, IP3 signaling, and Alzheimer's disease. Neuroscientist. 2005; 11(2):110-5. DOI: 10.1177/1073858404270899. View

Oules B, Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J . Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci. 2012; 32(34):11820-34. PMC: 3458216. DOI: 10.1523/JNEUROSCI.0875-12.2012. View

Lanner J, Georgiou D, Joshi A, Hamilton S . Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol. 2010; 2(11):a003996. PMC: 2964179. DOI: 10.1101/cshperspect.a003996. View

Pavlov P, Wiehager B, Sakai J, Frykman S, Behbahani H, Winblad B . Mitochondrial γ-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J. 2010; 25(1):78-88. DOI: 10.1096/fj.10-157230. View

Chan S, Mayne M, Holden C, Geiger J, Mattson M . Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem. 2000; 275(24):18195-200. DOI: 10.1074/jbc.M000040200. View

10.

Howlett D, Bate S, Collier S, Lawman A, Chapman T, Ashmeade T . Characterisation of amyloid-induced inflammatory responses in the rat retina. Exp Brain Res. 2011; 214(2):185-97. DOI: 10.1007/s00221-011-2819-4. View

11.

Bruno A, Huang J, Bennett D, Marr R, Hastings M, Stutzmann G . Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging. 2011; 33(5):1001.e1-6. PMC: 3160507. DOI: 10.1016/j.neurobiolaging.2011.03.011. View

12.

Ditlevsen D, Kohler L, Berezin V, Bock E . Cyclic guanosine monophosphate signalling pathway plays a role in neural cell adhesion molecule-mediated neurite outgrowth and survival. J Neurosci Res. 2007; 85(4):703-11. DOI: 10.1002/jnr.21175. View

13.

Bezprozvanny I . Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009; 15(3):89-100. PMC: 3226745. DOI: 10.1016/j.molmed.2009.01.001. View

14.

Zhang H, Liu J, Sun S, Pchitskaya E, Popugaeva E, Bezprozvanny I . Calcium signaling, excitability, and synaptic plasticity defects in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015; 45(2):561-80. PMC: 4814213. DOI: 10.3233/JAD-142427. View

15.

Britt B, KALOW W . Malignant hyperthermia: a statistical review. Can Anaesth Soc J. 1970; 17(4):293-315. DOI: 10.1007/BF03004694. View

16.

Tam J, Pasternak S . Amyloid and Alzheimer's disease: inside and out. Can J Neurol Sci. 2012; 39(3):286-98. DOI: 10.1017/s0317167100013408. View

17.

Folch J, Petrov D, Ettcheto M, Abad S, Sanchez-Lopez E, Garcia M . Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast. 2016; 2016:8501693. PMC: 4735913. DOI: 10.1155/2016/8501693. View

18.

Rajendran L, Paolicelli R . Microglia-Mediated Synapse Loss in Alzheimer's Disease. J Neurosci. 2018; 38(12):2911-2919. PMC: 6596066. DOI: 10.1523/JNEUROSCI.1136-17.2017. View

19.

Kelliher M, Fastbom J, Cowburn R, Bonkale W, Ohm T, Ravid R . Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience. 1999; 92(2):499-513. DOI: 10.1016/s0306-4522(99)00042-1. View

20.

Rybalchenko V, Hwang S, Rybalchenko N, Koulen P . The cytosolic N-terminus of presenilin-1 potentiates mouse ryanodine receptor single channel activity. Int J Biochem Cell Biol. 2007; 40(1):84-97. DOI: 10.1016/j.biocel.2007.06.023. View